These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1230 related items for PubMed ID: 19670189
1. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy. Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH. Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189 [Abstract] [Full Text] [Related]
2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC. Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [Abstract] [Full Text] [Related]
3. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group. Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978 [Abstract] [Full Text] [Related]
6. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B, Höcker B. Pediatr Transplant; 2006 Sep 27; 10(6):721-9. PubMed ID: 16911497 [Abstract] [Full Text] [Related]
7. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. Burkhalter F, Oettl T, Descoeudres B, Bachmann A, Guerke L, Mihatsch MJ, Dickenmann M, Steiger J. Transplant Proc; 2012 Dec 27; 44(10):2961-5. PubMed ID: 23195006 [Abstract] [Full Text] [Related]
9. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L. Clin J Am Soc Nephrol; 2012 Mar 27; 7(3):504-12. PubMed ID: 22282478 [Abstract] [Full Text] [Related]
10. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Knight RJ, Podder H, Kerman RH, Lawless A, Katz SM, Van Buren CT, Gaber AO, Kahan BD. Transplantation; 2010 Mar 27; 89(6):727-32. PubMed ID: 20195219 [Abstract] [Full Text] [Related]
11. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group. Kidney Int; 2019 Jul 27; 96(1):231-244. PubMed ID: 31027892 [Abstract] [Full Text] [Related]
12. Reduced exposure to calcineurin inhibitors in renal transplantation. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study. N Engl J Med; 2007 Dec 20; 357(25):2562-75. PubMed ID: 18094377 [Abstract] [Full Text] [Related]
14. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment. Pliszczynski J, Kahan BD. Transplant Proc; 2011 Dec 20; 43(10):3657-68. PubMed ID: 22172822 [Abstract] [Full Text] [Related]
15. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. Kaczmarek I, Zaruba MM, Beiras-Fernandez A, Reimann R, Nickel T, Grinninger C, Sadoni S, Hagl C, Meiser B. J Heart Lung Transplant; 2013 Mar 20; 32(3):277-84. PubMed ID: 23415313 [Abstract] [Full Text] [Related]
17. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor. Chen KH, Lee CY, Wu FL, Yang CY, Yeh CC, Hu RH, Tsai MK. J Formos Med Assoc; 2015 Jun 20; 114(6):526-31. PubMed ID: 25843527 [Abstract] [Full Text] [Related]
18. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS. Transplantation; 2015 Jan 20; 99(1):180-6. PubMed ID: 24983307 [Abstract] [Full Text] [Related]
19. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up. Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M. Transplant Proc; 2009 May 20; 41(4):1152-5. PubMed ID: 19460503 [Abstract] [Full Text] [Related]
20. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? Hanto DW, Chudzinski R. Transplantation; 2009 Jan 27; 87(2):164-5. PubMed ID: 19155968 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]